Live Breaking News & Updates on Diana Kwong

Stay updated with breaking news from Diana kwong. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Will Kidney Disease Patients Finally Receive New Drug Class?

Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change? ....

San Francisco , United States , Donalda Molony , Tazeenh Jafar , Diana Kwong , Drug Administration , Kidney Research Institute , University Of California , University Of Washington , Kidney Disease , Improving Global Outcomes , Gross Underuse , Medical School , Ian De Boer , Chi Yuan Hsu , Choosing Among Dapa , Chronic Renal Failure , Hronic Kidney Failure , Hronic Kidney Disease Ckd , Chronic Kidney Disease , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors , Renal Failure , Enal Insufficiency ,

Patients with AKI self-report high level of physical, emotional burdens

AUSTIN, Texas — Patients with AKI self-reported a high level of physical and emotional burdens, revealing fatigue to be one of the most common symptoms, according to a presenter at the National Kidney Foundation Spring Clinical Meetings.“We were interested in patient-reported outcomes, like the symptom burden and self-reported quality of life, among survivors of acute kidney injury ....

San Francisco , United States , Gina Brockenbrough , Byjulies Keenan , Y Diana Kwong , National Kidney Foundation Spring Clinical Meetings , University Of California , National Kidney Foundation Spring Clinical , Diana Kwong ,